Insight

Stephen V Liu on Phase 2 Study of Irinotecan plus Anlotinib for Platinum-Resistant SCLC

Stephen V Liu/X

Jun 25, 2025, 09:00

Stephen V Liu on Phase 2 Study of Irinotecan plus Anlotinib for Platinum-Resistant SCLC

Stephen V Liu, Director of Thoracic Oncology and Associate Professor of Medicine at Georgetown University, shared a post on X:

“Single arm phase II study of irinotecan + anlotinib for platinum-resistant SCLC published Lung Cancer Journal (n=37). RR 62%, PFS 4.5m, OS 7.2m.

Tarlatamab is the standard here but still need novel agents. Always hard to interpret single arm SCLC studies.”

Title: Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase Ⅱ study

Journal: Lung Cancer Journal

Article: Minna Zhang, Yi Tang, Jiafeng Liang, Lucheng Zhu, Bing Wang, Kaicheng Pan, Xiao Xu, Xueqin Chen, Bing Xia

Read the full article.

Stephen V Liu

More posts featuring Stephen V Liu on OncoDaily.

Bing Wang Bing Xia cancer Jiafeng Liang Kaicheng Pan Lucheng Zhu Lung Cancer Journal Minna Zhang OncoDaily Oncology SCLC Stephen V Liu Xiao Xu Xueqin Chen Yi Tang

BEATcc Trial at ESMOGynaec25: Atezolizumab Benefits Cervical Cancer Patients Regardless of PD-L1 Status

15 Posts Not to Miss from EACR 2025

ASCO 2025 RCC Advances: Expert Insights by Ilya Tsimafeyeu

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself